Mycosis fungoides: Current trends in diagnosis and management

Indian Journal of Dermatology

Volumn 52, Issue 1, 2007, Pages 5-20

  Panda, Saumya ^a  

^a Ruby General Hospital   (India)

Author keywords

Cutaneous lymphoma; Mycosis fungoides; Sezary syndrome; T lymphocytes

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTICONVULSIVE AGENT; BEXAROTENE; CARBAMAZEPINE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; FLUDARABINE; GEMCITABINE; IMATINIB; IMIQUIMOD; METHOTREXATE; OKT 4; PELDESINE; PENTOSTATIN; PHENOBARBITAL; PHENYTOIN; PSORALEN; TACROLIMUS; UNINDEXED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CHEMOTHERAPY; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTACT DERMATITIS; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ECZEMA; EDEMA; GASTROINTESTINAL STROMAL TUMOR; GRANULOMATOUS SKIN DISEASE; GRANULOMATOUS SLACK SKIN SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; HYPOPIGMENTATION; HYPOTENSION; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MEDICAL LITERATURE; MEDICATION ERROR; MELANOMA; METASTASIS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOBACTERIUM HAEMOPHILUM; MYCOSIS FUNGOIDES; NAUSEA; OPTIMAL DRUG DOSE; PATHOLOGICAL ANATOMY; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PSORIASIS; PUVA; RARE DISEASE; REVIEW; SECONDARY SYPHILIS; SEZARY SYNDROME; SIDE EFFECT; SKIN BIOPSY; VOMITING; WORINGER KOLOPP DISEASE;

EID: 34247550087     PISSN: 00195154     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5154.31918     Document Type: Review

References (156)

1. Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Mycosis fungoides and Sezary syndrome: An update. Curr Oncol Rep 2006;8:376-86.
2. Hess Schmid M, Dummer R, Kempf FW, Hilty N, Burg G. Mycosis fungoides with mucinosis follicularis in childhood. Dermatology 1999;198:284-7.
3. Elmer KB, George RM. Cutaneous T-cell lymphoma presenting as benign dermatoses. Am Fam Physician 1999;59:2809-13.
4. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999;89:1240-4.
5. Weinstock MA, Horn JW. Mycosis in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
6. Macey WH. A primary care approach to cutaneous T-cell lymphoma. Nurse Pract 2000;25:82,85-8,91-4 passim.
7. Neuhaus IM, Ramos-Caro FA, Hassanein AM. Hypopigmented mycosis fungoides in childhood and adolescence. Pediatr Dermatol 2000;17:403-6.
8. Rodriguez-Vazquez M, Garcia-Arpa M, Gonzalez-Garcia J. Juvenile mycosis fungoides treated with bexarotene and PUVA. Int J Dermatol 2007;46:99-102.
9. Tan E, Tay YK, Giam YC. Profile and outcome of childhood mycosis fungoides in Singapore. Pediatr Dermatol 2000;17:352-6.
10. Annessi G, Paradisi M, Angelo C, Perez M, Puddu P, Girolomoni G. Annular lichenoid dermatitis of youth. J Am Acad Dermatol 2003;49:1029-36.
11. Pabsch H, Rutten A, Van Stemm A, Meigel W, Sander CA, Schaller J. Treatment of childhood mycosis fungoides with topical PUVA. J Am Acad Dermatol 2002;47:557-61.
12. Whittaker S. Molecular genetics of cutaneous lymphomas. Ann NY Acad Sci 2001;941:39-45.
13. Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Allelotyping in mycosis fungoides and Sezary syndrome: Common regions of allelic loss identified on 9p, 10q and 17p. J Invest Dermatol 2001;117:663-70.
14. th Annual American Academy of Dermatology. Discussion Group 417: San Francisco, California; March 3-7, 2006.
15. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:1053-63.
16. van Doorn R, Van Haselen CW, van Voorst Vader PC, Geerts ML, Heule F, de Rie M, et al. Mycosis fungoides: Disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.
17. Goldenberg G. Cutaneous T-cell lymphoma: Focus on mycosis fungoides. Available from: http://www.medscape.com/viewarticle/529351. [Last accessed on 2007 Feb 17].
18. Akaraphanth R, Douglass MC, Lim HW. Hypopigmented mycosis fungoides: Treatment and a 6 1/2- year follow-up of 9 patients. J Am Acad Dermatol 2000;42:33-9.
19. Cordel N, Duval-Modeste AB, Courville P, Joly P. Hypopigmented mycosis fungoides. Ann Dermatol Venereol 2005;132:455-7.
20. Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1277-311.
21. LeBoit PE, Beckstead JH, Bond B, Epstein WL, Frieden IJ, Parslow TG. Granulomatous slack skin: Clonal rearrangement of the T-cell receptar beta gene is evidence for the lymphoproliferative nature of a cutaneous elastolytic disorder. J Invest Dermatol 1987;89:183-6.
22. Osiji N, Fearfield L, Matutes E, Wotherspoon AC, Bunker C, Catovsky D. Granulomatous slack skin disease - disease features and response to pentostatin. Br J Haematol 2003;123:297-304.
23. van Haselen CW, Toonstra J, van der Putte SJ, van Dongen JJ, van Hees Cl, van Vloten WA. Granulomatous slack skin. Report of three patients with an updated review of the literature. Dermatology 1988;196:382-91.
24. Fargnoli MC, Peris K, Francesconi F, Cantonetti M, Cerroni L, Chimenti S. Granulomatous mycosis fungoides responsive to gemcitabine. Eur J Dermatol 2002;12:479-81.
25. Wollina U, Graefe T, Foller J. Granulomatous slack skin or granulomatous mycosis fungoides - a case report. Complete response to percutaneous radiation and interferon alpha. J Clin Res Clin Oncol 2002;128:50-4.
26. Scarabello A, Leinweber B, Ardigo M, Rutten A, Feller AC, Kerl H, et al. Cutaneous lymphomas with prominent granulomatous reaction: A potential pitfall in the histopathologic diagnosis of cutaneous T-and B-cell lymphomas. Am J Surg Pathol 2002;26:1259-68.
27. Haller A, Elzubi E, Petzelbauer P. Localized syringolymphoid hyperplasia with alopecia and anhidrosis. J Am Acad Dermatol 2001;45:127-30.
28. Badawy E, D'Incan M, El Majjaoui S, Franck F, Fabricio L, Dereure O, et al. Ichthyosiform mycosis fungoides. Eur J Dermatol 2002;12:594-6.
29. Twersky JM, Mutassim DF. Mycosis fungoides presenting as reticular erythematous mucinosis. Int J Dermatol 2006;45:230-3.
30. Hur J, Seong JY, Choi TS, Jang JG, Jang MS, Suh KS, et al. Mycosis fungoides presenting as Ofuji's papuloerythroderma. J Eur Acad Dermatol Venereol 2002;16:393-6.
31. Saada D, Lami MC, Vabres P, Levillain P, Guillet G. Mycosis fungoides presenting as annular erythema. Ann Dermatol Venereol 2005;132:35-7.
32. Speron S, Gamelli R. Toxic epidermal necrolysis syndrome versus mycosis fungoides. J Burn Care Rehabil 1977;18:421-3.
33. Heliot I, Beylot-Barry M, Vergier B, Doutre MS, Beylot C. Cutaneous T-cell lymphoma bullosa: 2 cases. Ann Dermatol Venereol 2003;130:639-42.
34. Jang JG, Sim HJ, Kim SH, Doh KS, Jang MS, Suh KS, et al. Mycosis fungoides mimicking inflammatory linear verrucous epidermal nevus. J Eur Acad Dermatol Venereol 2004;18:218-20.
35. Yoo SS, Viglione M, Moresi M, Vonderheid E. Unilesional mycosis fungoides mimicking Bowen's disease. J Dermatol 2003;30:417-9.
36. Spieth K, Grundmann-Kollmann M, Runne U, Staib G, Fellbaum C, Wolter M, et al. Mycosis-fungoides-type cutaneous T-cell lymphoma of the hands and soles: A variant causing delay in diagnosis and adequate treatment of patients with palmoplantar eczema. Dermatology 2002;205:239-44.
37. Kim ST, Jeon YS, Sim HJ, Kim SH, Kim YK, Suh KS, et al. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris. J Am Acad Dermatol 2006;54:466-71.
38. Kiratli H, Gumus K. Mycosis fungoides of the eyelids. Two case reports. J Fr Ophthalmol 2006;29:323-6.
39. Vang R, Medeiros LJ, Malpica A, Levenback C, Deavers M. Non-Hodgkin's lymphoma involving the vulva. Int J Gynecol Pathol 2000;19:236-42.
40. Copur MS, Deshpande A, Mleczko K, Norvell M, Hrnicek GJ, Woodward S, et al. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in a patient with mycosis fungoides. Croat Med J 2005;46:458-62.
41. Poonawalla T, Chen W, Duvic M. Mycosis fungoides with tinea psuedoimbricata owing to Trichophyton rubrum infection. J Cutan Med Surg 2006;10:52-6.
42. Hubert JN, Callen JP. Recalcitrant tinea corporis as the presenting manifestation of patch stage mycosis fungoides. Cutis 2003;71:59-61.
43. Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated diseases: A 5-year retrospective study at Tamathibodi Hospital. J Med Assoc Thai 2005;88:678-81.
44. Tan HH, Tan A, Theng C, Ng SK. Cutaneous Mycobacterium haemophilum infection in immunocompromised patients in a dermatology clinic in Singapore. Ann Acad Med Singapore 2004;33:532-6.
45. Kobashi Y, Yoneyama H, Okimoto N, Matsushima T, Soejima R. Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy. Kekkaku 1999;74:789-95.
46. Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol 2003;42:116-22.
47. Liotta EA, Turiansky GW, Berberian BJ, Sulica VI, Tomaszewski MM. Unusual presentation of secondary syphilis in 2 HIV-1 positive patients. Cutis 2000;66:383-6,389.
48. Crum NF. Disseminated coccidioidomycosis with cutaneous lesions clinically mimicking mycosis fungoides. Int J Dermatol 2005;44:958-60.
49. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol 2003;148:730-6.
50. Gul U, Kilic A, Dursun A. Carbamazepine -induced pseudomycosis fungoides. Ann Pharmacother 2003;37:1441-3.
51. Miranda-Romero A, Perez-Oliva N, Aragoneses H, Bastida J, Raya C, Gonzalez-Lopez A, et al. Carbamazepine hypersensitivity syndrome mimicking mycosis fungoides. Cutis 2001;67:47-51.
52. Clark SH, Duvic M, Prieto VG. Mycosis fungoides- like reaction in a patient treated with Gleevec. J Cutan Pathol 2003;30:279-81.
53. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, et al. Hydroa-like cutaneous T-cell lymphoma: A clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002;10:7-14.
54. Khamaysi Z, Ben-Arieh Y, Epelbaum R, Bergman R. Pleomorphic CD8+ small / medium size cutaneous T-cell lymphoma. Am J Dermatopathol 2006;28:434-7.
55. Stein M, Farrar N, Jones GW, Wilson LD, Fox L, Wong RK et al. Central neurologic involvement in mycosis fungoides: Ten cases, actuarial risk assessment and predictive factors. Cancer J 2006;12:55-62.
56. Zonenshayn M, Sharma S, Hymes K, Knopp EA, Golfinos JG, Zagzag D. Mycosis fungoides metastasizing to the brain parenchyma: Case report. Neurosurgery 1998;42:933-7.
57. Beylot-Barry M, Dubus P, Vergier B, Cogrel O, Marit G, Beylot C, et al. Meningeal involvement by a transformed mycosis fungoides following Hodgkin's disease. Br J Dermatol 1999;141:909-13
58. deConinck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 2001;19:779-84.
59. Benedetti M, Niebel T, Tinozzi FP, Vassallo C, Brazzelli V, Paulli M, et al. Bilateral inguinal hernia with dislocation of great saphenous vein as complication of long-standing granulomatous slack skin: A case report. J Eur Acad Dermatol Venereol 2006;20:595-8.
60. Foss F. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol 2004;16:421-8.
61. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
62. Wieselthier JS, Koh HK. Sezary syndrome: Diagnosis, prognosis and critical review of treatment options. J Am Acad Dermatol 1990;22:381-401.
63. Balfour EM, Glusac EJ, Heald P, Talley LL, Smoller BR. Sezary syndrome: Cutaneous immunoperoxidase double-labeling technique demonstrates CD4/CD8 ratio non-specificity. J Cutan Pathol 2003;30:437-42.
64. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R; British Association of Dermatologists; U.K. Cutaneous Lymphoma Group. Joint British Association of Dermatologists and U.K. Cutaneous lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-107.
65. Kumar R, Xiu Y, Zhuang HM, Alavi A. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of priamary cutaneous lymphoma. Br J Dermatol 2006;155:357-63.
66. Aarset H, Skarsvag S, Ryggen K. Mycosis fungoides. Early diagnosis and evaluation of treatment by polymerase chain reaction. Tidsskr Nor Laegeforen 1997;117:3391-2.
67. Lenane P, Powell FC, O'keane C, Dervan P, O'Sullivan D, Bourke E, et al. Mycosis fungoides: A review of the management of 28 patients and of recent literature. Int J Dermatol 2007;46:19-26.
68. Dereure O, Balavoine M, Salles MT, Candon-Kerlau S, Clot J, Guilhou JJ, et al. Correlations between clinical, histologic, blood and skin polymerase chain reaction outcome in patients treated for mycosis fungoides. J Invest Dermatol 2003;121:614-7.
69. Tancre de-Bohin E, Ionescu MA, de La Salmoniere P, Dupuy A, Rivet J, Rybojad M, et al. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. Arch Dermatol 2004;140:1057-61.
70. th Annual American Academy of Dermatology. Symposium 303: San Francisco, California; March 3-7, 2006.
71. Nikolova M, Bagot M, Boumsell L, Bensussan A. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas. Leuk Lymphoma 2002;43:741-6.
72. Lozzi GP, Massone C, Citarella L, Kerl H, Cerroni L. Rimming of adipocytes by neoplastic lymphocyte: A histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol 2006;28:9-12.
73. Theinert SM, Pronest MM, Peris K, Sterry W, Walden P. Identification of the testis-specific protein 10 (TSGA 10) as serologically defined fumour-associated antigen in primary cutaneous T-cell lymphoma. Br J Dermatol 2005;153:639-41.
74. El-Darouti MA, Marzouk SA, Bosseila M, Zeid OA, El-Safouri O, Zayed A, et al. Microscopic study of normal skin in cases of mycosis fungoides. Int J Dermatol 2006;45:1043-6.
75. Delfau-Larue MH, Dalac S, Lepage E, Petrella T, Wechsler J, Farcet JP, et al. Prognostic significance of polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood 1998;92:3376-80.
76. Poszepczynska-Guigne E, Bagot M, Wechsler J, Revuz J, Farcet JP, Delfau-Larue MH. Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction. Br J Dermatol 2003;148:265-71.
77. Dummer R, Kamarashev J, Kempf W, Hoffner AC, Hess-Schmid M, Burg G. Junctional CD8+ cutaneous lymphomas with non-aggressive clinical behaviour: A CD8+ variant of mycosis fungoides? Arch Dermatol 2002;138:199-203.
78. Santucci M, Biggeri A, Feller AC, Burg G. Accuracy, concordance, and reproducibility of histologic diagnosis in cutaneous T-cell lymphoma: An EORTC Cutaneous Lymphoma Project Group Study. European Organization for Research and Treatment of Cancer. Arch Dermatol 2000;136:497-502.
79. Curce N, Servitje O, Llucia M, Beltran J, Limon A, Carmona M, et al. Genotypic analysis of cutaneous T-cell lymphoma: A comparative study of Southern blot analysis with polymerase chain reaction amplification of the T-cell receptor-gamma gene. Br J Dermatol 1997;137:673-9.
80. Santucci M, Pimpinelli N, Massi D, Kadin ME, Meijer CJ, Muller-Hermelink HK, et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-27.
81. Eros N, Karolyi Z, Matolcsy A. Complex histologic, immunophenotypic and molecular genetic investigation in cutataneous T-cell lymphoproliferative diseases. Orv Hetil 2004;145:75-80.
82. Su MW, Dorrocicz I, Dragowska WH, Ho V, Li G, Voss N, et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res 2003;63:7122-7.
83. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphama study group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
84. Grange F, Bagot M. Prognosis of primary cutaneous lymphomas. Ann Dermatol Venereol 2002;129:30-40.
85. Querfeld C, Rosen ST, Kuzel TM, Guitart J. Cutaneous T-cell lymphomas: A review with emphasis on new treatment approaches. Semin Cutan Med Surg 2003;22:150-61.
86. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
87. Ayyalaraju RS, Finlay AY, Dykes PJ, Trent JT, Kirsner RS, Kerdel FA. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: A comparative study. J Am Acad Dermatol 2003;49:249-54.
88. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998;134:949-54.
89. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:416-28.
90. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: Update of the Stanford experience. Arch Dermatol 2003;139:165-73.
91. Esteve E, Bagot M, Joly P, Souteyrand P, Beylot-Barry M, Vaillant L, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French study Group of Cutaneous Lymphomas. Arch Dermatol 1999;135:1349-53.
92. Zackheim H, Epstein E, Crain W. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: A 15-year experience in 143 patients. J Am Acad Dermatol 1990;22:802-10.
93. Duvic M, Olsen EA, Omura GA, Maize JC, Vonderheid EC, Elmets CA, et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;44:940-7.
94. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase I and II trial of bexarotene gel for skin directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol 2002;138:325-32.
95. Nguyen EQ, Wolverton S. Systemic retinoids. In: Wolverton S, editor. Comprehensive dermatologic drug therapy. WB Sunders: Philadelphia; 2001. p. 269-310.
96. Dummer R, Urosevic M, Kempf W, Kazakov D, Burg G. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003;207:116-8.
97. Rallis E, Economidi A, Verros C, Papadakis P. Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%. J Drugs Dermatol 2006;5:906-7.
98. Hermann JJ, Roenigk HH Jr, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, et al. Treatment of mycosis fungoides with photochemo-therapy: Long term follow-up. J Am Acad Dermatol 1995;33:234-42.
99. Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T Cell lymphoma. A follow-up study. J Am Acad Dermatol 1984;10:238-45.
100. Ramsey DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-3.
101. Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J. Narrowband TL-01 phototherapy for patch stage mycosis fungoides. Arch Dermatol 2000;136:748-52.
102. Zane C, Leali C, Airo P, De Panfilis G, Pinton PC. 'High dose' UVA1 therapy of widespread plaque type, modular and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001;44:629-33.
103. Gambichler T, Breuckmann F, Boms S, Altmeyer P, Kreuter A. Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 2005;52:660-70.
104. Nistico S, Costanzo A, Saraceno R, Chimenti S. Efficacy of monochromatic excimer laser radiation (308 nm) in the treatment of early stage mycosis fungoides. Br J Dermatol 2004;151:877-9.
105. Upjohn E, Foley P, Lane P, Magee J, Prince HM, McCormack C, et al. Long-term clearance of patch-stage mycosis fungoides with the 308-nm laser. Clin Exp Dermatol 2007;32:168-71.
106. Nayak CS. Photodynamic therapy in dermatology. Indian J Dermatol Venereol Leprol 2005;71:155-60.
107. Hamminga B, Van Noordijk EM, Vloten WA. Treatment of mycosis fungoides: Total skin electrol beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982;118:150-3.
108. Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-70.
109. Hagedorn M, Hasche E, Kober B, Sander CA. Long term results of total skin electron beam therapy (TSEBT) in the treatment of mycosis fungoides. Hautarzt 2003;54:256-64.
110. Micaily B, Miyamoto C, Kantor G, Lessin S, Rook A, Brady L, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 1998;42:361-4.
111. Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA Cutaneous T-Cell Lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys 1998;40:109-15.
112. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen musterd alone as initial treatment of T2 and T3 myosis fungoides. Int J Radiat Oncol Biol Phys 1999;43:951-8.
113. Bunn PA Jr, Ihde De, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphoma. Cancer 1986;57:1689-95.
114. Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH Jr, Diab N, et al. Interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20:395-407.
115. Papa G, Tura S, Mandelli F, Vegna ML, Defazio D, Mazza P, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991;79:48-51.
116. Kuzel TM, Roenigk HH Jr, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995;13:257-63.
117. Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999;94:902-8.
118. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, Bunn PA Jr. Phase II study of recombinant interferon gamma for treatment of cutaneous T-cell lymphoma. J Nat Cancer Inst 1990;82:208-12.
119. Mougel F, Dalle S, Balme B, Houot R, Thomas L. Aggressive CD30 large cell lymphoma after cyclosporine given for putative atropic dermatitis. Dermatology 2006;213:239-41.
120. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994;121:592-602.
121. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: A report on ten patients with follow-up. J Cancer Res Clin Oncol 2001;127:128-34.
122. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J Clin Oncol 2000;18:2603-6.
123. Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, et al. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. Semin Oncol 2000;27:52-7.
124. Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, et al. Pentostatin in T-cell malignancies - a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999;10:1493-8.
125. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001;114:624-31.
126. Burt RK, Guitart J, Traynoor A, Link C, Rosen S, Pandolfino T, et al. Allogeneic haematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft versus tumour effect. Bone Marrow Transplant 2000;25:111-3.
127. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory sezary syndrome after bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999;5:400-4.
128. Knox S, Hoppe RT, Maloney D, Gibbs I, Fowler S, Marquez C, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996;87:893-9.
129. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y - T101, in patients with CD5-expressing leukaemia and lymphoma. Clin Cancer Res 1998;4:2691-70.
130. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Senin Oncol 2006;33:S44-52.
131. McFarlane V, Friedmann PS, Illidge TM. What's new in the management of cutaneous T-cell lymphoma? Clin Oncol 2005;17:174-84.
132. Wong SF. Oral bexarotene in the treatment of cutaneous Tcell lymphoma. Ann Pharmacother 2001;35:1056-65.
133. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, et al. Minimizing adverse side effects of oral bexarotene in cutaneous T-cell lymphoma: An expert opinion. Br J Dermatol 2006;155:261-6.
134. Huber MA, Kunzi-Rapp K, Staib G, Scharffetter-Kochanek K. Management of refractory early stage cutaneous T-cell lymphoma (mycosis fungoides) with a combination of oral bexarotene and psoralen plus ultraviolet bath therapy. J Am Acad Dermatol 2004;50:475-6.
135. Moss FM. New insights into the mechanism of action of extracorporeal photopheresis. Transfusion 2006;46:6-8.
136. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photopheresis. J Am Acad Dermatol 1992;27:427-33.
137. Evans AV, Wood BP, Scarisbrick JJ, Fraser-Andrews EA, Chinn S, Dean A, et al. Extracorporeal photopheresis in Sezary syndrome: Hematologic parameters as predictors of response. Blood 2001;98:1298-301.
138. Girardi M, Berger C, Hanlon D, Edelson RL. Efficient tumour antigen loading of dendritic antigen presenting cells by transimmunization. Technol Cancer Res Treat 2002;1:65-9.
139. Foss F. Overview of cutaneous T-cell lymphoma: Prognostic factors and novel therapeutic approaches. Leuk Lymphoma 2003;44:S55-61.
140. Elhassadi E, Egan E, O'sullivan G, Mohamed R. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol 2006;28:279-81.
141. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K. Management of refractory early stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006;7:155-69.
142. Wood GS. Management of cutaneous T-cell lymphoma: The future is here. J Am Acad Dermatol 2001;45:317.
143. Eichmuller S. Towards defining specific antigens for cutaneous lymphomas. Onkologie 2002;25:448-54.
144. Ramez M, Bagot M, Nikolova M, Boumsell L, Vita N, Chalon P, et al. Functional characterization of neurotensin receptors in human cutaneous T-cell lymphoma malignant lymphocytes. J Invest Dermatol 2001;117:687-93.
145. Vacca A, Ribatti D, Ria R, Pellegrino A, Bruno M, Merchionne F, et al. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev Immunol 2000;7:77-8.
146. Parker SR, Bradley B. Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatol Nurs 2006;18:566-70.
147. Panasiti V, Devirgilis V, Borroni RG, Rossi M, Curzio M, Mancini M, et al. Management of skin ulcers in a patient with mycosis fungoides. Dermatol Online J 2006;12:16.
148. Mays SR, Bogle MA, Bodey GP. Cutaneous fungal infections in the oncology patient: Recognition and management. Am J Clin Dermatol 2006;7:31-43.
149. Topar G, Zelger B, Schmuth M, Romani N, Thaler J, Sepp N. Granulomatous slack skin: A distinct disorder or a variant of mycosis fungoides? Acta Derm Venereol 2001;81:42-4.
150. Morales MM, Putcha V, Evans HS, Olsen J, Llopis A, Moller H. Survival of mycosis fungoides in patients in the Southeast of England. Dermatology 2005;211:325-9.
151. Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 2006;31:181-6.
152. Siegel RS, Kuzel TM. Cutaneous T-cell lymphoma leukemia. Curr Treat Options Oncol 2000;1:43-50.
153. Capizzi R, Rotoli M, Cavalieri S, Amerio P. Hypopigmental mycosis fungoides in a 12-year-old Caucasian girl with solely hypopigmented lesions. Dermatology 2003;207:201-2.
154. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: A practical marriage of two giants. Br J Dermatol 2005;153:874-80.
155. Kawahira K. Immunohistochemical staining of proliferating cell nuclear antigen (PCNA) in malignant and nonmalignant skin diseases. Arch Dermatol Res 1999;291:413-8.
156. Mori M, Campolmi P, Mavilia L, Rossi R, Cappugi P, Pimpinelli N. Monochromatic excimer light (308nm) in patch-stage IA mycosis fungoides. J Am Acad Dermatol 2004;50:943-5.